[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Blinatumomab\" }]"}]},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","commit":"e6207f1815","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/regimens.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"cancers"},{"field":"setting"},{"field":"intent"},{"field":"cycleDays"},{"field":"cycles"},{"field":"components"},{"field":"emetogenicity"},{"field":"gcsf"},{"field":"trials"},{"field":"source"},{"field":"notes"},{"field":"asOf"}]},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first T-cell engager (2014), now given to children and adults with leukaemia even when in remission, because it improves survival.\"","after":"\"Blinatumomab was the first T-cell engager (2014), and is now given to children and adults with leukaemia even when in remission, because it improves survival.\""}]}]